SCHEMBL2756014

SCHEMBL2756014

COc1ccc(OC)c(CN[C@H]2CC2c2ccccc2)c1

nearest known ligand 0.77

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 19/20 0.77
MAOA P21397 13/20 0.77
MAOB P27338 11/20 0.77
TACR1 P25103 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238969 1.00 KDM1A (0.77) KDM1AMAOAMAOBTACR1
SCHEMBL238968 1.00 KDM1A (0.77) KDM1AMAOAMAOBTACR1
Hydrochloric Acid SCHEMBL238690 0.99 KDM1A (0.76) KDM1AMAOAMAOBTACR1
Hydrochloric Acid SCHEMBL238689 0.99 KDM1A (0.76) KDM1AMAOAMAOBTACR1
SCHEMBL7000327 0.90 KDM1A (0.77) KDM1AMAOAMAOB
SCHEMBL7000328 0.90 KDM1A (0.77) KDM1AMAOAMAOB
SCHEMBL7000330 0.90 KDM1A (0.77) KDM1AMAOAMAOB
SCHEMBL237944 0.87 KDM1A (1.00) KDM1AMAOAMAOBTACR1
SCHEMBL2755995 0.87 KDM1A (1.00) KDM1AMAOAMAOBTACR1
SCHEMBL237943 0.87 KDM1A (1.00) KDM1AMAOAMAOBTACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160045456-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE ORYZON GENOMICS S.A. (ES) 2016-02-18 US disclosed
US-20160045456-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE ORYZON GENOMICS S.A. (ES) 2016-02-18 US disclosed
US-8993808-B2 Phenylcyclopropylamine derivatives and their medical use ORYZON GENOMICS, S.A. (ES) 2015-03-31 US disclosed
US-8993808-B2 Phenylcyclopropylamine derivatives and their medical use ORYZON GENOMICS, S.A. (ES) 2015-03-31 US disclosed
US-20120004262-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE ORYZON GENOMICS, S.A. (ES) 2012-01-05 US disclosed
US-20120004262-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE ORYZON GENOMICS, S.A. (ES) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004262-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE PNMT, ABCB1, SNCA KDM1A 1515/4885MAOA 80/4885MAOB 143/4885
US-20160045456-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE PNMT, ABCB1, SNCA KDM1A 1515/4885MAOA 80/4885MAOB 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.